The Reformulation Playbook: How Pharma Uses 505(b)(2) to Lock In New Patents, Block Generics, and Reset Prices
Pharma’s “Reformulation Playbook” Is the New Patent Arms Race—And 505(b)(2) Is the Weapon
If you think generic competition is a straight line—patent expires, prices fall, patients win—think again. The industry has learned to bend that timeline. And one…
